Skip to main content

Table 4 Age-specific comparison of standard gamble utility scores converted using the ‘12 month-early stage cervical cancer’ score

From: A survey of population-based utility scores for cervical cancer prevention

Health state

Age groups

Wilcoxan rank sum test P value

20-49 years

50-69 years

Mean utility score

Median utility score (IQR)

Mean utility score

Median utility score

(SE)

 

(SE)

(IQR)

Cytology normal

0.9938

0.9997

0.9990

0.9999

0.4932

(0.0055)

(0.9994 - 1.0)

(0.0004)

(0.9994 - 1.0)

HPV vaccination

0.9992

0.9998

0.9539

1.0

0.6534

( 0.0004)

(0.9994 - 1.0)

( 0.0454)

(0.9996 - 1.0)

LG cytology

0.9935

0.9997

0.9563

0.9998

0.2855

(0.0055)

(0.9993 - 0.9999)

(0.0429)

(0.9996 - 1.0)

LG cytology with colposcopy normal

0.9909

0.9997

0.9563

0.9997

0.3383

(0.0070)

(0.9950 - 0.9999)

(0.0420)

(0.9969 - 1.0)

HPV positive with cytology normal

0.9942

0.9997

0.9552

0.9997

0.3379

(0.003955)

(0.9959 - 0.9999)

( 0.0434)

(0.9977 - 1.0)

HPV positive with colposcopy normal

0.9934

0.9997

0.9990

0.9998

0.1280

( 0.0045)

(0.9950 - 0.9999)

(0.0004)

(0.9989 - 0.9999)

Treated genital warts

0.9894

0.9997

0.9532

0.9997

0.2483

( 0.0056)

(0.9950 - 0.9999)

( 0.0454)

(0.9990 - 1.0)

HG cytology with CIN 1

0.9956

0.9997

0.9523

0.9996

0.3725

( 0.0024)

(0.9950 - 0.9997)

(0.0420)

(0.9977 - 0.9999)

HG cytology with CIN 2 or 3

0.9908

0.9995

0.9527

0.9996

0.2826

(0.0049)

(0.9948 - 0.9997)

(0.0433)

(0.9983 - 1.0)

Early stage cervical cancer

0.7977

0.9450

0.8352

0.960

0.2616

(0.0819)

(0.8850 - 0.9750)

(0.0709)

(0.915 - 0.995)

  1. HPV human papillomavirus; LG low grade disease; HG high grade disease; CIN cervical intraepithelial neoplasia; FIGO Fédération Internationale de Gynécologie Obstétrique (International Federation of Gynecology and Obstetrics.